Novartis Version of Enbrel Is Similar to Amgen’s, FDA Staff Says

  • Enbrel is Amgen’s top-selling drug at $5.36 billion in 2015
  • Novartis’s drug is a biosimilar, or near-copy, of Amgen’s

Novartis AG’s biosimilar version of the arthritis drug Enbrel, which the Swiss company is seeking to sell in the U.S. market, is comparable to the original made by Amgen Inc., U.S. regulators said.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.